Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes PharmaphorumAstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.Metabolic & GLP-1Read full story pharminent June 9, 2026 (Last updated: June 11, 2026) Pharmaphorum AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA. Metabolic & GLP-1 Read full story Post navigation Previous: Pfizer’s Hympavzi secures FDA expanded indications for haemophiliaNext: ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026